Tipiracil Hydrochloride

盐酸替匹嘧啶

Report date: 2024/01/02 20:03:52
NME

Base Information

Drug NameTipiracil Hydrochloride
Drug Alias Name盐酸替吡拉西替匹嘧啶盐酸盐替吡拉西盐酸盐替吡嘧啶盐酸替比拉西 +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionThymidine phosphorylase inhibitorsAngiogenesis inhibitorsDNA synthesis inhibitors
TargetsThymidine phosphorylase
Therapy Area/IndicationsStomach NeoplasmsEsophageal NeoplasmsAdenocarcinoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesTaiho Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer Institute
Inactive CompaniesN/A
Active IndicationsStomach NeoplasmsEsophageal NeoplasmsAdenocarcinoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksKEGG